Allergic Conjunctivitis Market Size to Surpass USD 4.26 Billion by 2030, exhibiting a CAGR of 5.7%

As per the report by Fortune Business Insights, The Global Allergic Conjunctivitis Market size is projected to reach USD 4.26 Billion by 2030, at a CAGR of 5.7% during the forecast period.

Allergic Conjunctivitis Market

Allergic Conjunctivitis Market (2023-2030)
Allergic Conjunctivitis Market (2023-2030)

Pune, India, Aug. 28, 2023 (GLOBE NEWSWIRE) -- The global allergic conjunctivitis market size was USD 2.74 billion in 2022 and it is projected to grow from USD 2.89 billion in 2023 to USD 4.26 billion by 2030, exhibiting a CAGR of 5.7% during the forecast period. Allergic conjunctivitis is a disorder where the eye's conjunctiva inflates due to an allergic reaction resulting from an individual’s interaction with an allergen.

This disease affects a considerable proportion of the global population but is often underdiagnosed and ignored by the patient and the healthcare professional.

Fortune Business Insights™ mentioned this in a report titled “Allergic Conjunctivitis Market, 2023-2030.”

Key Industry Development:

  • March 2022: Johnson & Johnson Vision Care, Inc. declared the approval of ACUVUE Theravision with Ketotifen by U.S. FDA.


Request a Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/allergic-conjunctivitis-market-100121


Key Takeaways:

  • The FDA in the United States has approved etafilcon, a drug-eluting contact lens containing ketotifen, under the brand name ACUVUE Theravision, according to Johnson & Johnson Vision Care, Inc.

  • Pataday Once Daily Relief Extra Strength is now widely available at retail locations in the United States, according to Alcon.

  • Alaway Preservative Free Antihistamine Eye Drops, the first over-the-counter (OTC) preservative-free formulation eye drop, was introduced by Bausch & Lomb.

  • The first brand-new, prescription-only medication for allergic conjunctivitis in the United States in ten years, ZERVIATE (cetirizine ophthalmic solution) 0.24%, was just released, according to Eyevance Pharmaceuticals LLC.

Discover the Leading Players Featured in the Report:

Major players in the allergic conjunctivitis market are Allergan (AbbVie Inc.) (U.S.), Santen Pharmaceutical Co., Ltd. Japan), Bausch & Lomb Incorporated (Canada), Alcon (Switzerland), Novartis AG (Switzerland), Eyevance Pharmaceuticals LLC (U.S.), Sun Pharmaceutical Industries Ltd. India), Ocular Therapeutix, Inc. (U.S.), Eton Pharmaceutical (U.S.)

Report Scope

Report Coverage

Details

Forecast Period

2023 to 2030

Forecast Period 2023 to 2030 CAGR

5.7%

2030 Value Projection

USD 4.26 Billion

Base Year

2022

Market Size in 2023

USD 2.89 Billion

Historical Data for

2019 to 2021

No. of Pages

140


Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/allergic-conjunctivitis-market-100121